Their findings hint at the promising potential of dietary interventions aimed at modulating the gut microbiota as a therapeutic strategy for the treatment of chronic multifocal osteomyelitis (CMO) arising from PSTPIP2 deficiency. Here, PSTPIP2 is linked to chronic recurrent multifocal osteomyelitis.